|
Synonyms: burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023
burosumab is an approved drug (EMA & FDA (2018))
Compound class:
Antibody
Comment: Burosumab (KRN23) is a fully human anti-FGF-23 monoclonal antibody. Anti-FGF-23 mAbs are considered suitable for prevention or treatment of diseases which are caused by hyperactivity of FGF-23 or for diseases whose pathology might be improved by controlling FGF-23 activity [1,4].
Annotated peptide sequences for this antibody are available from its IMGT/mAb-DB record. BLAST peptide anaylsis reveals identical matches with peptides claimed in patent US7883705, with the claimed antibody being abbreviated to 'C10' in the document (full identifier N5KG1_C10_LH) [11]. |
Classification  |
|
| Compound class | Antibody |
| Approved drug? | Yes (EMA & FDA (2018)) |
| International Nonproprietary Names |
|
| INN number | INN |
| 10301 | burosumab |
| Synonyms |
| burosumab-twza | Crysvita® | KRN-23 | KRN23 | N5KG1_C10_LH | UX-023 | UX023 |
| Database Links |
|
| Specialist databases | |
| IMGT/mAb-DB | 647 |
| Other databases | |
| GtoPdb PubChem SID | 318164811 |
| Search PubMed clinical trials | burosumab |
| Search PubMed titles | burosumab |
| Search PubMed titles/abstracts | burosumab |
